drugset / Trial / NCT00435461

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00435461 ↗

Phase 4 Completed 1000 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine

Timeline

Start
2006-12-20
Primary completion
2007-02-01
Completion
2007-02-28

Outcome

Met primary endpoint

registry analysis (superiority or other test); FFNS 110 mcg vs Fex 180 mg; p <0.001; Mean Difference (Final Values) -0.9 (95% CI -1.2 to -0.7); ANCOVA NCT00435461 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown — —
Subject Fluticasone Furoate Other / unclassified — —